Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 60 articles:
HTML format
Text format



Single Articles


    February 2017
  1. VERA CA, Orostica L, Gabler F, Ferreira A, et al
    The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells.
    Int J Oncol. 2017 Feb 28. doi: 10.3892/ijo.2017.3892.
    PubMed     Text format     Abstract available


  2. PARK SH, Chung YJ, Song JY, Kim SI, et al
    Mullerian inhibiting substance inhibits an ovarian cancer cell line via beta-catenin interacting protein deregulation of the Wnt signal pathway.
    Int J Oncol. 2017 Feb 13. doi: 10.3892/ijo.2017.3874.
    PubMed     Text format     Abstract available


  3. ZHU X, Ji M, Han Y, Guo Y, et al
    PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
    Int J Oncol. 2017 Feb 10. doi: 10.3892/ijo.2017.3873.
    PubMed     Text format     Abstract available


    November 2016
  4. TURCONI G, Scaldaferri D, Fabbri M, Monti L, et al
    RNASET2 silencing affects miRNAs and target gene expression pattern in a human ovarian cancer cell model.
    Int J Oncol. 2016 Nov 9. doi: 10.3892/ijo.2016.3763.
    PubMed     Text format     Abstract available


    October 2016
  5. XIE Q, Su J, Jiao B, Shen L, et al
    ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
    Int J Oncol. 2016 Oct 13. doi: 10.3892/ijo.2016.3733.
    PubMed     Text format     Abstract available


    September 2016
  6. CHEN WC, Hsu HP, Li CY, Yang YJ, et al
    Cancer stem cell marker CD90 inhibits ovarian cancer formation via beta3 integrin.
    Int J Oncol. 2016 Sep 15. doi: 10.3892/ijo.2016.3691.
    PubMed     Text format     Abstract available


  7. LEE J, An S, Choi YM, Lee J, et al
    Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Int J Oncol. 2016 Sep 6. doi: 10.3892/ijo.2016.3683.
    PubMed     Text format     Abstract available


  8. PUVANENTHIRAN S, Essapen S, Seddon AM, Modjtahedi H, et al
    Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Int J Oncol. 2016 Sep 5. doi: 10.3892/ijo.2016.3678.
    PubMed     Text format     Abstract available


  9. MASUYAMA H, Nakamura K, Nobumoto E, Hiramatsu Y, et al
    Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
    Int J Oncol. 2016;49:1211-20.
    PubMed     Text format     Abstract available


    August 2016
  10. WU W, Wang Q, Yin F, Yang Z, et al
    Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
    Int J Oncol. 2016 Aug 10. doi: 10.3892/ijo.2016.3652.
    PubMed     Text format     Abstract available


    June 2016
  11. CHEN C, Chang YC, Lan MS, Breslin M, et al
    [Corrigendum] Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
    Int J Oncol. 2016 Jun 6. doi: 10.3892/ijo.2016.3564.
    PubMed     Text format     Abstract available


  12. XIANG XY, Kang JS, Yang XC, Su J, et al
    SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells.
    Int J Oncol. 2016 Jun 1. doi: 10.3892/ijo.2016.3552.
    PubMed     Text format     Abstract available


  13. WANG D, Saga Y, Sato N, Nakamura T, et al
    The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
    Int J Oncol. 2016;48:2303-9.
    PubMed     Text format     Abstract available


    May 2016
  14. QI X, Du L, Chen X, Chen L, et al
    VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.
    Int J Oncol. 2016 May 17. doi: 10.3892/ijo.2016.3527.
    PubMed     Text format     Abstract available


    April 2016
  15. HABATA S, Iwasaki M, Sugio A, Suzuki M, et al
    BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
    Int J Oncol. 2016 Apr 21. doi: 10.3892/ijo.2016.3494.
    PubMed     Text format     Abstract available


  16. TU Y, Kim E, Gao Y, Rankin GO, et al
    Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
    Int J Oncol. 2016 Apr 6. doi: 10.3892/ijo.2016.3472.
    PubMed     Text format     Abstract available


    March 2016
  17. LIU R, Martin TA, Jordan NJ, Ruge F, et al
    Epithelial protein lost in neoplasm-alpha (EPLIN-alpha) is a potential prognostic marker for the progression of epithelial ovarian cancer.
    Int J Oncol. 2016 Mar 29. doi: 10.3892/ijo.2016.3462.
    PubMed     Text format     Abstract available


  18. ZHOU B, Sun C, Li N, Shan W, et al
    Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
    Int J Oncol. 2016 Mar 15. doi: 10.3892/ijo.2016.3442.
    PubMed     Text format     Abstract available


  19. AGUILAR-ROJAS A, Perez-Solis MA, Maya-Nunez G
    The gonadotropin-releasing hormone system: Perspectives from reproduction to cancer (Review).
    Int J Oncol. 2016;48:861-8.
    PubMed     Text format     Abstract available


  20. MANKARIOUS A, Dave F, Pados G, Tsolakidis D, et al
    The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro.
    Int J Oncol. 2016 Mar 1. doi: 10.3892/ijo.2016.3410.
    PubMed     Text format     Abstract available


    February 2016
  21. ZHAO M, Wei C, Yang X, Zhou J, et al
    The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes.
    Int J Oncol. 2016 Feb 12. doi: 10.3892/ijo.2016.3390.
    PubMed     Text format     Abstract available


  22. ANTONILLI M, Rahimi H, Visconti V, Napoletano C, et al
    Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
    Int J Oncol. 2016 Feb 8. doi: 10.3892/ijo.2016.3386.
    PubMed     Text format     Abstract available


    January 2016
  23. LI L, Yu J, Duan Z, Dang HX, et al
    The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.
    Int J Oncol. 2016 Jan 25. doi: 10.3892/ijo.2016.3355.
    PubMed     Text format     Abstract available


  24. SKIRNISDOTTIR I, Seidal T, Akerud H
    The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.
    Int J Oncol. 2016 Jan 12. doi: 10.3892/ijo.2016.3333.
    PubMed     Text format     Abstract available


    November 2015
  25. NAKAYAMA K, Rahman MT, Rahman M, Nakamura K, et al
    CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Int J Oncol. 2015 Nov 26. doi: 10.3892/ijo.2015.3268.
    PubMed     Text format     Abstract available


  26. GAO Y, Rankin GO, Tu Y, Chen YC, et al
    Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways.
    Int J Oncol. 2015 Nov 20. doi: 10.3892/ijo.2015.3257.
    PubMed     Text format     Abstract available


  27. LIU X, Zou J, Su J, Lu Y, et al
    Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
    Int J Oncol. 2015 Nov 19. doi: 10.3892/ijo.2015.3254.
    PubMed     Text format     Abstract available


  28. TAN H, He Q, Gong G, Wang Y, et al
    miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.
    Int J Oncol. 2015 Nov 9. doi: 10.3892/ijo.2015.3241.
    PubMed     Text format     Abstract available


  29. DENG Z, Wang L, Hou H, Zhou J, et al
    Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/beta-catenin signaling.
    Int J Oncol. 2015 Nov 4. doi: 10.3892/ijo.2015.3228.
    PubMed     Text format     Abstract available


    October 2015
  30. MIURA R, Yokoyama Y, Shigeto T, Futagami M, et al
    Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.
    Int J Oncol. 2015 Oct 13. doi: 10.3892/ijo.2015.3205.
    PubMed     Text format     Abstract available


  31. WAN J, Shi F, Xu Z, Zhao M, et al
    Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
    Int J Oncol. 2015 Oct 13. doi: 10.3892/ijo.2015.3201.
    PubMed     Text format     Abstract available


  32. TAKAHASHI Y, Saga Y, Koyanagi T, Takei Y, et al
    The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.
    Int J Oncol. 2015 Oct 8. doi: 10.3892/ijo.2015.3193.
    PubMed     Text format     Abstract available


  33. KATAGIRI H, Nakayama K, Razia S, Nakamura K, et al
    Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
    Int J Oncol. 2015 Oct 6. doi: 10.3892/ijo.2015.3191.
    PubMed     Text format     Abstract available


    September 2015
  34. MA L, Xu Y, Su J, Yu H, et al
    Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function.
    Int J Oncol. 2015 Sep 21. doi: 10.3892/ijo.2015.3176.
    PubMed     Text format     Abstract available


    August 2015
  35. LIU R, Martin TA, Jordan NJ, Ruge F, et al
    Metastasis suppressor 1 expression in human ovarian cancer: The impact on cellular migration and metastasis.
    Int J Oncol. 2015 Aug 13. doi: 10.3892/ijo.2015.3121.
    PubMed     Text format     Abstract available


  36. SO KA, Min KJ, Hong JH, Lee JK, et al
    Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition.
    Int J Oncol. 2015 Aug 13. doi: 10.3892/ijo.2015.3122.
    PubMed     Text format     Abstract available


  37. JI F, Chang X, Liu C, Meng L, et al
    Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9.
    Int J Oncol. 2015 Aug 6. doi: 10.3892/ijo.2015.3115.
    PubMed     Text format     Abstract available


    July 2015
  38. LI Z, Sun L, Lu Z, Su X, et al
    Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system.
    Int J Oncol. 2015 Jul 10. doi: 10.3892/ijo.2015.3079.
    PubMed     Text format     Abstract available


  39. YANG Y, Bucan V, Baehre H, von der Ohe J, et al
    Acquisition of new tumor cell properties by MSC-derived exosomes.
    Int J Oncol. 2015;47:244-52.
    PubMed     Text format     Abstract available


    May 2015
  40. KIM NY, Lee HY, Lee C
    Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Int J Oncol. 2015 May 12. doi: 10.3892/ijo.2015.3004.
    PubMed     Text format     Abstract available


  41. PASTOREK M, Simko V, Takacova M, Barathova M, et al
    Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.
    Int J Oncol. 2015 May 5. doi: 10.3892/ijo.2015.2987.
    PubMed     Text format     Abstract available


    April 2015
  42. LIU X, Gao Y, Zhao B, Li X, et al
    Discovery of microarray-identified genes associated with ovarian cancer progression.
    Int J Oncol. 2015 Apr 20. doi: 10.3892/ijo.2015.2971.
    PubMed     Text format     Abstract available


  43. TAKENAKA M, Saito M, Iwakawa R, Yanaihara N, et al
    Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
    Int J Oncol. 2015 Apr 3. doi: 10.3892/ijo.2015.2951.
    PubMed     Text format     Abstract available


  44. CHEN J, Chen AY, Huang H, Ye X, et al
    The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway.
    Int J Oncol. 2015 Apr 1. doi: 10.3892/ijo.2015.2946.
    PubMed     Text format     Abstract available


    March 2015
  45. QIU JJ, Lin YY, Ding JX, Feng WW, et al
    Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer.
    Int J Oncol. 2015 Mar 31. doi: 10.3892/ijo.2015.2943.
    PubMed     Text format     Abstract available


  46. WANG Y, Han A, Chen E, Singh RK, et al
    The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.
    Int J Oncol. 2015 Mar 17. doi: 10.3892/ijo.2015.2931.
    PubMed     Text format     Abstract available


  47. WEN C, Liu X, Ma H, Zhang W, et al
    miR3383p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2.
    Int J Oncol. 2015 Mar 16. doi: 10.3892/ijo.2015.2929.
    PubMed     Text format     Abstract available


    February 2015
  48. SU M, Chang W, Cui M, Lin Y, et al
    Expression and anticancer activity analysis of recombinant human uPA143-melittin.
    Int J Oncol. 2015;46:619-26.
    PubMed     Text format     Abstract available


    January 2015
  49. TAKAYA A, Peng WX, Ishino K, Kudo M, et al
    Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Int J Oncol. 2015 Jan 28. doi: 10.3892/ijo.2015.2858.
    PubMed     Text format     Abstract available


    December 2014
  50. OSAWA Y, Yokoyama Y, Shigeto T, Futagami M, et al
    Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.
    Int J Oncol. 2014 Dec 30. doi: 10.3892/ijo.2014.2810.
    PubMed     Text format     Abstract available


  51. SUH Y, Jo S, Lee H, Lee C, et al
    Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
    Int J Oncol. 2014 Dec 23. doi: 10.3892/ijo.2014.2808.
    PubMed     Text format     Abstract available


    November 2014
  52. LI J, Liu T, Zhao L, Chen W, et al
    Ginsenoside 20(S)Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells.
    Int J Oncol. 2014 Nov 18. doi: 10.3892/ijo.2014.2767.
    PubMed     Text format     Abstract available


  53. SAYASNEH A, Ekechi C, Ferrara L, Kaijser J, et al
    The characteristic ultrasound features of specific types of ovarian pathology (Review).
    Int J Oncol. 2014 Nov 18. doi: 10.3892/ijo.2014.2764.
    PubMed     Text format     Abstract available


  54. BRACHOVA P, Mueting SR, Carlson MJ, Goodheart MJ, et al
    TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Int J Oncol. 2014 Nov 11. doi: 10.3892/ijo.2014.2747.
    PubMed     Text format     Abstract available


    October 2014
  55. SUN Q, Yogosawa S, Iizumi Y, Sakai T, et al
    The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Int J Oncol. 2014 Oct 8. doi: 10.3892/ijo.2014.2703.
    PubMed     Text format     Abstract available


  56. YI BR, Kim TH, Kim YS, Choi KC, et al
    Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
    Int J Oncol. 2014 Oct 7. doi: 10.3892/ijo.2014.2695.
    PubMed     Text format     Abstract available


    June 2014
  57. OTTE A, Rauprich F, von der Ohe J, Hillemanns P, et al
    Interference of Ca2+ with the proliferation of SCCOHT-1 and ovarian adenocarcinoma cells.
    Int J Oncol. 2014 Jun 24. doi: 10.3892/ijo.2014.2518.
    PubMed     Text format     Abstract available


    April 2014
  58. VAN TILBORG AA, Sweep FC, Geurts-Moespot AJ, Wetzels AM, et al
    Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
    Int J Oncol. 2014;44:1394-400.
    PubMed     Text format     Abstract available


    March 2014
  59. WANG Y, Li L, Qu Z, Li R, et al
    The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.
    Int J Oncol. 2014 Mar 27. doi: 10.3892/ijo.2014.2359.
    PubMed     Text format     Abstract available


    January 2014
  60. WANG X, Gui L, Zhang Y, Zhang J, et al
    Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-beta signaling pathway.
    Int J Oncol. 2014 Jan 21. doi: 10.3892/ijo.2014.2261.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: